14. The use according to claim 13, wherein the medicament prevents, reduces or slows the progression of fibrosis.

15. The use according to claim 13, wherein the medicament reduces established fibrosis.

16. The use according to claim 13, wherein the medicament restores normal tissue architecture.

17. The use according to any one of claims 13 to 16, wherein the fibrosis is myocardial fibrosis, kidney fibrosis and/or liver fibrosis.

18. The use according to claim 13, wherein the medicament prevents, reduces or slows fat accumulation in the liver.

19. The use according to claim 13, wherein the medicament prevents, reduces or slows renal tubular cell death.

20. The use according to claim 13, wherein the medicament restores normal tissue architecture.